Fidaxomicin
| Clinical data | |
|---|---|
| Trade names | Dificid, others |
| Other names | Clostomicin B1, lipiarmicin, lipiarmycin, lipiarmycin A3, OPT-80, PAR 01, PAR-101, tiacumicin B |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Macrolide antibacterial |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Minimal systemic absorption |
| Elimination half-life | 11.7 ± 4.80 hours |
| Excretion | Urine (<1%), faeces (92%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.220.590 |
| Chemical and physical data | |
| Formula | C52H74Cl2O18 |
| Molar mass | 1058.05 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fidaxomicin, sold under the brand name Dificid among others, is an antibiotic medication used for the treatment of C. difficile-associated diarrhea. It is a macrolide antibacterial and is the first member of a class of narrow spectrum macrocyclic antibiotic drugs called tiacumicins. It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis.
Fidaxomicin was approved for medical use in the United States in May 2011. It is available as a generic medication.